ReviewHuman vaccines & immunotherapeutics2018
Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.
Review in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Meningococcal meningitis in India: An expert consensus on use of MCVs.Human vaccines & immunotherapeutics · 2026Pooled it
- Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.Human vaccines & immunotherapeutics · 2021Trial
- Potential Use of Neisseria meningitidis Serogroup B Vaccines to Prevent Neisseria gonorrhoeae Infection: Epidemiological Considerations.Journal of the International AIDS Society · 2026Review
- Safety Profile of the 4CMenB (BexseroVaccines · 2025Review
- Outer Membrane Vesicles as a Versatile Platform for Vaccine Development: Engineering Strategies, Applications and Challenges.Journal of extracellular vesicles · 2025Review
- Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review.Human vaccines & immunotherapeutics · 2024Review
- Transforming vaccinology.Cell · 2024Review
- Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.Human vaccines & immunotherapeutics · 2023Review
- Article
- Review
- Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review.Infectious diseases and therapy · 2023Review
- Invasive Disease Due toMicroorganisms · 2023Article
- Four-Component Recombinant Protein-Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy.JAMA network open · 2023Article
- Two centuries of vaccination: historical and conceptual approach and future perspectives.Frontiers in public health · 2023Review
- Proceedings of the Expert Consensus Group meeting on meningococcal serogroup B disease burden and prevention in India.Human vaccines & immunotherapeutics · 2022Article
- Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.Infectious diseases and therapy · 2022Review
- Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.Human vaccines & immunotherapeutics · 2021Article
- Meningococcal vaccines in China.Human vaccines & immunotherapeutics · 2021Article
- Travelers' vaccines and their adverse events in Nara, Japan.Open medicine (Warsaw, Poland) · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeningococcal disease (MD) is a major cause of meningitis and sepsis worldwide, with a high case fatality rate and frequent sequelae. Neisseria meningitidis serogroups A, B, C, W, X and Y are responsible for most of these life-threatening infections, and its unpredictable epidemiology can cause outbreaks in communities, with significant health, social and economic impact. Currently, serogroup B is the main cause of MD in Europe and North America and one of the most prevalent serogroups in Latin America. Mass vaccination strategies using polysaccharide vaccines have been deployed since the 1970s and the use of conjugate vaccines has controlled endemic and epidemic disease caused by serogroups A, C, W and Y and more recently serogroup B using geographically-specific outer membrane vesicle based vaccines. Two novel protein-based vaccines are a significant addition to our armamentarium against N. meningitidis as they provide broad coverage against highly diverse strains in serogroup B and other groups. Early safety, effectiveness and impact data of these vaccines are encouraging. These novel serogroup B vaccines should be actively considered for individuals at increased risk of disease and to control serogroup B outbreaks occurring in institutions or specific regions, as they are likely to save lives and prevent severe sequelae. Incorporation into national programs will require thorough country-specific analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.